Interested in this peptide?
Request more information and our team will get back to you within 2 business days.
What Is Semax?
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH). Developed in Russia at the Institute of Molecular Genetics, it consists of the ACTH(4-7) fragment with an added Pro-Gly-Pro sequence that increases stability and bioactivity. Semax has been approved in Russia and Ukraine for various neurological indications.
Semax is notable for retaining nootropic and neuroprotective properties of ACTH fragments while lacking significant hormonal effects.
Key Characteristics
- Category: Nootropic peptide
- Administration: Typically intranasal
- Duration: Effects last several hours
- Hormonal Effects: Minimal (unlike full ACTH)
Development History
- 1980s: Developed at Russian Academy of Sciences
- 1990s: Clinical trials and approval in Russia
- Indications (Russia): Stroke, cognitive disorders, optic nerve disease
- Current status: Prescription drug in Russia; research compound in West
Mechanism of Action
Neurotrophic Effects
Semax influences brain-derived neurotrophic factor (BDNF) and related pathways:
- Increases BDNF expression in the brain
- Upregulates TrkB receptor signaling
- Promotes neuronal survival and plasticity
- Enhances NGF (nerve growth factor) expression
Melanocortin System
Interacts with melanocortin receptors (MC3R, MC4R):
- Activates central melanocortin pathways
- May influence cognition via MC4R
- Does not significantly affect ACTH/cortisol (unlike full ACTH)
Dopamine System
- Modulates dopaminergic transmission
- May increase dopamine turnover in certain brain regions
- Potential effects on attention and motivation
Serotonin System
- Influences serotonergic activity
- May affect mood and anxiety
Neuroprotective Mechanisms
- Antioxidant activity
- Anti-inflammatory effects in brain tissue
- Protection against excitotoxicity
- Improved cerebral blood flow
Research and Clinical Applications
Stroke Recovery (Russian Studies)
- Approved indication in Russia
- Studies show improved cognitive recovery
- Better functional outcomes reported
- Used in acute and rehabilitation phases
Cognitive Enhancement
- Improved attention and memory in various studies
- Enhanced learning in animal models
- Increased mental clarity reported
- May reduce mental fatigue
Optic Nerve Atrophy
- Approved in Russia for optic nerve diseases
- May preserve visual function
- Neuroprotective effects on retinal ganglion cells
Anxiety and Depression
- Some studies suggest anxiolytic effects
- Possible antidepressant properties
- May relate to BDNF and serotonin effects
Key Published Research
| Year | Focus | Key Finding | Reference |
|---|---|---|---|
| 1999 | Stroke | Improved recovery in ischemic stroke | Gusev et al. |
| 2006 | BDNF | Increased BDNF gene expression | Agapova et al. |
| 2010 | Neuroprotection | Anti-inflammatory brain effects | Medvedeva et al. |
| 2014 | Gene expression | Broad transcriptome effects | Dolotov et al. |
Formulations and Variants
Semax Variants
- Semax (standard): Original formulation
- N-Acetyl Semax: Acetylated version, may have enhanced effects
- N-Acetyl Semax Amidate: Further modified for increased potency/duration
- Concentration: Typically 0.1% or 1% nasal solution
Administration
- Route: Intranasal (most common)
- Russian doses: 200-1000 mcg daily
- Duration: Often 10-14 day courses
- Onset: Effects typically within 1-2 hours
Side Effects
Generally considered well-tolerated:
- Nasal irritation (with intranasal use)
- Mild headache (uncommon)
- Hair loss reported by some users (rare, reversible)
- Vivid dreams
- Emotional sensitivity in some individuals
Comparison: Semax vs Selank
| Feature | Semax | Selank |
|---|---|---|
| Base peptide | ACTH(4-7) | Tuftsin |
| Primary effect | Cognitive enhancement | Anxiolytic |
| BDNF effects | Strong | Moderate |
| Anxiety reduction | Moderate | Strong |
| Immune effects | Limited | More pronounced |
Research Status
While Semax is approved in Russia and Ukraine, it is not FDA-approved and has not undergone rigorous clinical trials meeting Western standards. Most published research comes from Russian institutions. It is available only as a research compound in most Western countries. Independent verification of efficacy claims is limited.
Summary
Semax represents an interesting approach to nootropic and neuroprotective therapy, utilizing a modified ACTH fragment to achieve cognitive benefits without hormonal side effects. Its approval and clinical use in Russia provides some validation, though Western clinical trials are lacking. The proposed mechanisms — BDNF enhancement, melanocortin activation, and neuroprotection — make it a subject of ongoing scientific interest in cognitive research.